Replimune: Binary RP1 PDUFA Outcome and Funding Overhang Justify Hold Rating

Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Replimune Group. The associated price target remains the same with $11.00.

Evan Seigerman has given his Hold rating due to a combination of factors, primarily the binary nature of the upcoming April 10 PDUFA outcome for RP1. While the recent departure of a key FDA figure and acceptance of the resubmitted BLA modestly enhance perceived approval odds, he sees ongoing political and media pressures on the agency as limiting conviction on any single regulatory scenario.

At the same time, he recognizes that RP1 appears to be a meaningful therapy in an area of significant unmet need and could anchor a viable skin cancer franchise if approved. However, despite Replimune’s current cash providing a runway through the decision and early launch activities, a further CRL would leave the company with an uncertain path and likely inadequate funding for new pivotal work, justifying a neutral, wait‑and‑see stance.

In another report released yesterday, TipRanks – PerPlexity also upgraded the stock to a Hold with a $7.00 price target.